Scientific Advisory Board
Denis Coleman, MSME, MSMS, PhD
Dr. Coleman cofounded Symantec, a world leader in information security and the maker of Norton antivirus software. Today Symantec is a Fortune 500 company with over 18,000 employees and more than $6 billion in annual revenue. Dr. Coleman has helped start 14 companies in such diverse fields as optical character recognition, targeted Internet advertising, social networking software, and, most recently, biotechnology. One of his most well-known, game-changing inventions was the development of the first spell checker for a microcomputer, originally marketed in 1980 through a company called Innovative Software. He has served variously as early board member, founder, software designer/developer in 11 other startups, three of which had IPOs, including Neoforma, an online medical supply and equipment marketplace, Visioneer a hardware/software office imaging solutions, now merged with Nuance, and Financial Engines. Dr. Coleman earned his undergraduate degree and two Masters degrees from the Massachusetts Institute of Technology, and a PhD from Stanford University.
Mr. Melohn spent the last 25 years immersed in the Internet and the world of distributed systems. He most recently served as Vice President, Chief Technology Officer of Network Systems at Cisco Systems where his team produced over 200 patents, including work in applied cryptography, network address translation, quality of service, keying infrastructure, secure tunneling and configuration, and many other areas. Mr. Melohn and his team were twice winners of Cisco’s Pioneer Technology Award and was one of the top engineering teams to bring innovation to Cisco’s product line. Prior to joining Cisco, Mr. Melohn was at Sun Microsystems, where he created the Internet Engineering Group. He has co-authored several Internet RFCs, including Requirements for Internet Hosts and the Point-to-Point Protocol. He was director of Software Engineering at file server maker Auspex Systems, and the director of network engineering at Silicon Graphics where he and his team designed the world’s fastest TCP/IP-based network equipment, file servers, and web server platforms. At FlowWise Networks, Mr. Melohn was VP of Engineering where he led the team that designed a routing accelerator that won numerous industry awards. Mr. Melohn earned his undergraduate degree from the University of Southern California.
Michael Sailor, MS, PhD
Dr. Sailor is a Professor of Chemistry and Biochemistry and the Leslie Orgel Scholar in Inorganic Chemistry at the University of California, San Diego with affiliate appointments in the Department of Bioengineering and the Department of Nanoengineering. He is on the executive steering committee for UCSD’s Materials Science PhD Program and a member of the Moores Cancer Center at UCSD. Dr. Sailor is widely regarded as one of the leading global authorities on porous silicon. He has authored over 200 research publications in subjects related to nanotechnology, biomaterials, chemistry, sensors and electrochemistry, and is a named inventor on over 25 issued or pending patents. Dr. Sailor is on the editorial advisory board of the journals Advanced Materials, Advanced Healthcare Materials, ACS Nano, and Chemical Communications. He also has served on the United States Air Force Scientific Advisory Board, for which he earned the US Air Force’s Award for Meritorious Civilian Service. Dr. Sailor earned his undergraduate degree from Harvey Mudd College and a Masters and PhD from Northwestern University.
Ronald Saldarini, PhD
Dr. Saldarini is the founder and owner of Biological Initiatives, a private consulting firm providing service to the vaccines and pharmaceutical industry. Prior to that, he was President of the global vaccine business of Wyeth Pharmaceuticals (now part of Pfizer Inc.), during which time the company introduced several new vaccine products, including Prevnar, HibTiter, Tetramune, Acel-Imune, PnuImune 23, Meningicoccus C conjugate and Rotavirus. Dr. Saldarini has served on the board of a number of pharmaceutical and med-tech companies, including as the Lead Director of Medarex, Inc. until its sale in 2009 to Bristol Myers, as Chairman of Idun Pharmaceuticals, until its sale to Pfizer in 2006, and as Chairman of Cellegy Pharmaceuticals, Therion Biologicals, Alphavax, and Medavante, Inc. He is Second Vice Chairman and member of the Board of Trustees of Community Blood Services of Paramus, N.J. where he the Chairman of the New Jersey Umbilical Cord Blood Bank Scientific & Medical Advisory Panel. Dr. Saldarini has long provided service to the health community, including serving on three committees of the National Academy of Sciences Institute of Medicine, the Malaria Vaccine Initiative the National Vaccine Advisory Commission, the Blue Ribbon Search Committee for the selection of the Food and Drug Administration Commissioner, the Board of Trustees of the National Foundation of Infectious Disease, the Immunization Advisory Council of the New York Department of Health, the Policy Board of the Albert B. Sabin Vaccine Foundation, and the Corporate Council for the Children’s Health Fund. Dr. Saldarini earned his undergraduate degree from Drew University and a PhD from the University of Kansas.